NVS Novartis AG

-0.13  -0%
Previous Close 89.27
Open 89.36
Price To Book 4.33
Market Cap 204,513,440,255
Shares 2,294,294,820
Volume 422,116
Short Ratio 2.02
Av. Daily Volume 1,874,125

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Head-to-head trial versus proposed biosimilar adalimumab initiated. Expected completion 2022.
Cosentyx (secukinumab) - SURPASS
Ankylosing spondylitis (AS)
Approval announced April 30, 2018.
Tafinlar (dabrafenib) and Mekinist (trametinib)
Melanoma with BRAF V600E or V600K mutations
Phase 3 trial to be completed 2H 2020.
Metastatic castration-resistant prostate cancer (mCRPC)
Approval announced May 11, 2018.
Multiple Sclerosis (MS)
Phase 1 data at AAN May 5, 2019 noted motor function gains.
Zolgensma AVXS-101 STRONG
Spinal muscular atrophy (SMA) Type 2
FDA Approval announced June 22, 2017.
Tafinlar (dabrafenib) and Mekinist (trametinib)
Non-small cell lung cancer (NSCLC) with BRAF V600E mutation
Approval announced May 1, 2018.
Kymriah (CTL019 )- JULIET
Cancer - Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 3 updated data at ASCO June 4, 2017.
Ribociclib + Letrozole - MONALEESA-2
Breast cancer
CRL issued May 2, 2018.
Biosimilar rituximab
Various blood cancers, rheumatoid arthritis.
Priority review granted February 22, 2017. Approval announced May 26, 2017.
First-line use in patients with ALK+ metastatic NSCLC
Phase 3 data due by the end of 2019.
Ruxolitinib - REACH 3
Steroid-refractory chronic GVHD (Graft versus host disease)
Phase 3 data due 2H 2019.
Ruxolitinib - REACH 2
Steroid-refractory acute GVHD (Graft versus host disease)
CRL announced October 18, 2018.
ACZ885 (canakinumab)
CV risk reduction
Phase 3 data released March 22, 2017 - primary endpoints not met.
Acute heart failure
PDUFA date under priority review estimated October 15, 2019 using six-month timeline. Exact date not provided by company.
RTH258 (brolucizumab)
Neovascular AMD
Phase 3 trial to be completed 3Q 2019.
Phase 3 data due 2H 2019.
QAW039 (fevipiprant)
Phase 3 trial met primary endpoint - November 8, 2017.
Breast cancer - (pre-menopausal)
Phase 3 data due 2H 2019.
OMB157 (ofatumumab)
Relapsing multiple sclerosis
Phase 3 data presented at ASCO 2018 - PFS 20.5 months v 12.8 months
Kisqali plus fulvestrant: MONALEESA-3
Breast cancer - (post-menopausal)
Phase 3 data due 2H 2019.
Entresto - PARAGON
HF-pEF (heart failure with preserved ejection fraction)
Phase 3 trial completion due 2H 2020.
Entresto - PARADISE
AMI (acute myocardial infarction)
Approval announced early - August 30, 2017.
Kymriah (CTL019)
Relapsed/Refractory B-Cell Acute lymphoblastic leukemia
Approval announced May 17, 2018.
Phase 3 ongoing. Expected completion 2024.
CNP 520
Alzheimer’s Disease
Priority review granted November 14, 2016. Approval announced April 28, 2017.
Rydapt (Midostaurin - PKC412)
Acute myeloid leukemia (AML)
Priority review granted November 1, 2016. Approval announced March 13, 2017.
HR+/HER2- advanced breast cancer
FDA approval announced October 31, 2018.
Rheumatoid Arthritis
Approved January 26, 2018. Acquired from Advanced Accelerator Applications (NASDAQ: AAAP).
Inoperable progressive midgut NETs
FDA Approval announced May 24, 2019.
Zolgensma AVXS-101
Spinal muscular atrophy (SMA) Type 1
Phase 3 data May 5, 2019 noted 11/22 patients who could sit without support for at least 30 seconds. To be completed in 2021.
Zolgensma AVXS-101 STR1VE EU
Spinal muscular atrophy (SMA) Type 1
Phase 2 interim analysis 1H 2018.
Non-alcoholic steatohepatitis (NASH)
Phase 2 released October 19, 2018. ORR 72% in treatment-naive patients, 39% in previously treated patients.
Non-small cell lung cancer
Program discontinued - noted July 18, 2018.
FDA Approval announced May 24, 2019.
BYL719 + fulvestrant
HR + Metastatic breast cancer (MBC)
FDA approval announced February 8, 2018.
Phase 3 data May 5, 2019 noted all patients (18/18) were alive and event-free. Completion 2021.
Zolgensma AVXS-101 SPRINT
Pre-symptomatic patients with spinal muscular atrophy (SMA) Types 1, 2 and 3
sNDA approval announced November 16, 2018.
Promacta (eltrombopag)
Severe aplastic anemia (SAA)
FDA approval announced March 26, 2019.
Mayzent (siponimod/BAF312)
Secondary progressive multiple sclerosis
Phase 3 data due 2H 2019.
BRAFV600 mutant metastatic melanoma
Phase 3 data noted 46% reduction in serious clinical outcomes endpoint.
Entresto - PIONEER
Heart failure
Regulatory filing due 1H 2019.
Sickle cell disease
Phase 3 trial completed 1Q 2019.
Entresto - PARALLEL-HF
Heart failure
Phase 3 data due 2H 2019.
Cosentyx (secukinumab) - PREVENT
Non-radiographic axial spondyloarthritis
FDA Approval announced February 13, 2019.
BLA filing resubmission announced April 3, 2019 in response to CRL issued in 2017. Estimated PDUFA date February 3, 2020.
Biosimilar pegfilgrastim
Pegfilgrastim biosimilar
Phase 3 trial to be completed 2022.
Heart failure
Phase 3 trial to be completed 2021.
Entresto - Panorama
Heart failure
Phase 3 trial met primary endpoint.
Phase 3 trials met primary endpoints - June 3, 2019.
Xolair (omalizumab)
Chronic rhinosinusitis with nasal polyps (CRSwNP)
Phase 2/3 trial discontinued due to lack of efficacy.
Alzheimer’s Disease

Latest News

  1. Novartis' (NVS) Crizanlizumab Gets Priority Review From FDA
  2. Eton's Ophthalmic Solution Candidate Gets CRL, Shares Fall
  3. J&J Falls Amid Reports of Criminal Probe Into Talcum Powder
  4. GSK to appoint Jonathan Symonds as chairman
  5. What Happened in the Stock Market Today
  6. Amgen & Novartis' Alzheimer Studies End in Another Failure
  7. Novartis, Amgen Scrap Pivotal Study Of Alzheimer's Prevention Drug
  8. Aimmune Down on Negative ICER Review on Allergy Candidate
  9. Dow Jones Futures: Illumina, Profitable Marijuana Stock Tumble; Amgen-Novartis Alzheimer's Drug Fails
  10. The Daily Biotech Pulse: Hookipa Leaps, Illumina Dims On Q2 Warning, Novartis-Amgen Halt Alzheimer's Study
  11. Amgen and Novartis drop Alzheimer's-prevention study after patients worsened
  12. Signature Select Canadian Fund's Top 6 Buys
  13. Amneal (AMRX) Down on Guidance Update & Restructuring Plan
  14. Amgen, Novartis abandon two Alzheimer’s drug studies
  15. Glaxo's Two-Drug HIV Pill Dovato on Par with Three-Drug Pill
  16. How This Novartis Mashup Could Validate A Biotech Company's Cancer Drug
  17. The 10 Biggest Healthcare Stocks
  18. EpiPen Shortage: Mylan (MYL) Stock Falls on Continued Scarce Supply
  19. Jazz (JAZZ) Acquires Early-Stage Precision Oncology Asset
  20. Mylan Falls on Report That EpiPen Shortage Is Hurting Patients and Pharmacists